Treximo

Currently, there are no FDA or European Medicines Agency approved treatments for Alopecia Areata, a rare autoimmune disease in which the immune system attacks the hair follicles, leading to hair loss. However, Pfizer reported positive top-line data on its clinical trial for Ritlecitinib with a 20% or less scalp hair loss: https://bit.ly/3jqrUoK

Pfizer’s ritlecitinib meets primary efficacy goal in alopecia areata trial Pfizer has reported positive top-line data from the Phase IIb/III ALLEGRO trial of its drug, ritlecitinib, in alopecia areata patients.

A significant breakthrough might be coming by the end of the year, led by GentiBio, which recently gained funding of $157 million. GentiBio is developing regulatory T-Cell Therapies to cure and treat Type 1 diabetes and some auto-immune and inflammatory diseases. Read the whole story here: https://bit.ly/2WFBzz6

GentiBio raises $157M as cell therapy for immune diseases draw investor interest The biotech company is working with regulatory T cells, an immune cell type that's become the focus of several newly launched drugmakers like Abata Therapeutics and Sonoma Biotherapeutics.